Mechelen, Belgium; 13 November 2009 – Galapagos NV (Euronext: GLPG) announces today that third quarter 2009 operational and financial results were in line with management expectations. These results encourage the Company to retain full year guidance of €100 million revenues, a growth of 30% compared to 2008. Galapagos’ service division BioFocus will significantly increase its cash contribution to the Group result for the full year 2009. With operational cash burn also on track, Galapagos management increases guidance for year-end 2009 cash position to €38 million due to the successful €18.2 million private placement completed in October.

Galapagos also achieved progress in its development programs in the third quarter. The Company announced that its most advanced first-in-class program, GLPG0259 for rheumatoid arthritis, demonstrated safety and an excellent pharmacokinetic profile in a first Phase I study; this compound started a second Phase I study in September. Galapagos has completed its first-in-human trial for the IRA program in bone metastasis (GLPG0187) and expects to announce top-line results at the start of 2010. With Nanocort starting Phase II studies for the treatment of MS flares shortly and the first candidate drug from the osteoarthritis alliance with GSK entering the clinic next month, Galapagos is on-track to have four programs in clinical development by the end of 2009.

Furthermore in the third quarter, the Company announced milestones in its arthritis alliance with GlaxoSmithKline and its osteoporosis alliance with Lilly. BioFocus signed agreements with Procter & Gamble and Schering-Plough, and strengthened its network of cutting-edge capabilities through partnerships with Oncodesign and DiscoveRx. In September, Galapagos announced a collaboration with Charley’s Fund and the Nash Avery Foundation to investigate the potential effectiveness of Galapagos’ SARM candidate drug (GLPG0492) for the treatment of Duchenne muscular dystrophy. In October, Galapagos reached the first milestone in the anti-infectives alliance with GlaxoSmithKline and expanded the metabolic diseases alliance with Merck & Co to include atherosclerosis.

About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a drug discovery and development company with small molecule programs in bone and joint diseases, bone metastasis, cachexia, anti-infectives and metabolic diseases. It has established risk sharing alliances with GlaxoSmithKline, Janssen Pharmaceutica, Eli Lilly and Merck and Co. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases. Its division BioFocus offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. Galapagos currently employs 495 people and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More info at: www.glpg.com

CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com

This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.